RYBREVANT: A Breakthrough in Lung Cancer Treatment

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi

Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder

Revolutionizing Biology: AlphaFold 3 by Isomorphic and DeepMind Expands Beyond Protein Predictions

AlphaFold 3, Isomorphic, DeepMind, protein predictions, biology revolution, artificial intelligence, machine learning, structural biology, drug discovery, disease research.